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Introduction
In people with epilepsy, the inter-relationship between glucose and seizure provocation is not well understood. Glucose is an important energy source during seizure, nonketotic elevations may predispose to focal seizures while failure of glucose transport into the central nervous system can predispose to epilepsy. [1, 2] Regional glucose uptake or hypometabolic changes in possible epileptogenic tissue may become evident with 18F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) mapping. [3] In patients with type 1 diabetes mellitus (T1DM), seizures may be provoked with hypo, hyper and ketotic glycemia. [4] [5] [6] Yet how alterations in glucose changes seizure susceptibility is not well described. The responsive neurostimulation system (RNS, NeuroPace, Mountain View, CA) reduces self-reported seizure frequencies in patients with drug-resistant focal epilepsy. [7] The RNS surveys electrocorticography, which is trained to recognize physicianselected patterns associated with seizure onset, and then triggers electrical stimulation(s) or therapies designed to help mitigate or ideally terminate seizure.
Depending on where the electrodes are placed, the device can survey and record two different locations for seizure activity. That time-stamped data uploads to an onlineaccessible format for provider review, including if the stimulation failed and the event turned into an obvious electrical seizure.
In diabetes management, continuous glucose monitoring (CGM) is increasingly used to target insulin dosing and glucose response. [8, 9] (Dexcom monitoring systems, San Diego, CA) can continuously survey tissue glucose with data uploads every 5-minutes
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A C C E P T E D M A N U S C R I P T 5 to an online repository. [9] CGM estimates tissue glucose and needs near daily calibration between the device and blood glucose (finger sticks) surveyed with a separate functional glucometer. Our index patient has both the RNS and CGM devices, she regularly calibrates her CGM and the two devices are time synchronized. We assume, based on humans and animal models, that tissue glucose parallels glucose availability to the central nervous system. [10, 11] From studying these data sets, we aim to describe relationships between tissue glucose and seizures in this patient.
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Material and methods
After informed consent medical histories including data from CGM and RNS devices were studied in a patient with drug-resistant bitemporal epilepsy and T1DM for relationships between left focal seizures (LFS) or right focal seizures (RFS) by outcomes time of seizure and glucose. Consecutive RNS long events (LE) were reviewed by a board certified Epileptologist and considered as seizure proxies. Seizures were not studied unless glucose data was available at the time of seizure, only one seizure per day, the first, was used. The closest CGM reading prior to seizure onset was studied (tissue glucose is typically recorded every five minutes). Ultradian trends in glucose were also studied immediately after seizure and in the hours prior and post seizure. In this study, tissue glucose was considered a proxy for glucose levels within the central nervous system.
A control group was set up based on random date generations during the study period at the exact time of left or right focal seizures. I.e. for every seizure detected off the left or right side, a control glucose from different date was assigned based on the exact event time provided that no seizure on the control day occurred and that glucose data was available. Two controls were studied, one based only on glucoses from seizure-free times matched to LFS or RFS seizure times, and a second based on glucose from seizure-free times matched to any seizure. Two-tailed independent sample T-tests were run with variables including tissue glucose by side of seizure onset and control.
Trends in tissue glucose in the hour prior to and post event were studied with Chi 2 .
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A N U S C R I P T Only one intracranial subclinical event was recorded off of a right lateral inferior temporal location at an edge-of-grid location. Frequent interictal hippocampal discharges from the right hippocampus were noted. The second electrode was placed in the right hippocampus, assuming that place would prove important either as a generator or as a network hub for seizure spread. 
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Discussion
This is the first paper to our knowledge that looks closely at seizure and glucose at time of seizure events in an ambulatory patient. The data is most significant for right side Are there nonketotic glucose levels-high or low-that predispose to seizure?
We reviewed the literature on glucose levels and seizure provocation in humans. Almost all of it documents post-event or intra-event glucose such as in status epilepticus, and almost none of it clarifies glucose at seizure onset or prior to events. In 53,505 emergency responses to seizure, when glucose was checked, only 1% of presentations had finger sticks of ≤ 60 mg/dl, while the average was 112 mg/dl suggesting that most seizures occur with a relatively normal glucose. [12] That study did not report hyperglycemic presentations. In neonates with hypoglycemic seizures, ≤ 50 mg/dL is considered low. [13] In children with complex or prolonged febrile seizures, 10% had stress hyperglycemia post event, defined as ≥ 150mg/dl. [14] Data correlating what levels of nonketotic hyperglycemia are associated with seizure provocation is harder to find, most series are small, post event and range from 300-900 mg/dL. [15, 16] Importantly, serum glucose and CSF glucose are likely different, serum runs higher than
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A C C E P T E D M A N U S C R I P T 11 CSF, we would speculate a similar relationship to tissue (as measured by CGM) and CSF glucose. [11] What is absent from the literature are glucose levels that differ by locations of onset in patients with epilepsy. Perhaps the most relevant cite is in children with Landau-Kleffner syndrome (continuous spike and wave discharges during sleep)
where ultradian and regionalized glucose utilization (either hypo or hyper metabolic changes) where seen with FDG-pet during wake and sleep. [17] What's the relationship between type I diabetes mellitus and epilepsy?
T1DM is comorbid with epilepsy, with a hazard ratio of 2.89 [4] [5] [6] . Most T1DM patients are diagnosed with diabetes on average 2.8 years prior to their epilepsy, in this patient, the opposite was true. [4] Independent of risks of seizure from low or elevated glucose levels, individuals with T1DM may be prone to reflex epilepsy, our patient has a history reflex/audiogenic seizure, though we do not know which of her seizures were audiogenic to then correlate her glucose or laterality with. [18] There may be shared autoimmune risks due to anti-GAD antibody present in up to 80% type I diabetics and 6% of people with epilepsy. [4] [5] [6] GAD helps convert glutamate to gamma-aminobutyric acid (GABA), that process is contingent also on glucose through citric acid cycles. We do not know if this patient has anti-GAD antibodies.
Glucose manipulation as anti-seizure therapy, are there examples?
Anti-seizure diets such as low glycemic, modified Atkins or ketogenic all rely on marked reduction in carbohydrates and promotion of fat metabolism with the aim being ketosis and/or glucose lowering. [19] Ketosis involves acetoacetate, acetone and ßhydroxybutarate formation, which in turn helps lower pH and glucose utilization, which
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12 diminishes seizure activity. Anti-seizure drugs can alter glucose utilization. Oral glucose tolerance testing post IV valproic acid (VPA) infusions show rapid decrement of serum glucose, perhaps suggesting alternate VPA mechanism(s) of action. [20] Similarly when lamotrigine was administered to patients with generalized epilepsy, regionalized decreases in FDG-PET uptake were noted. [21] Topiramate is associated with clinical weight loss, seizure betterment and improved glucose control. [22] Anti-diabetic medications may also alter seizure control, in animals, metformin, a medicine used in type 2 diabetes mellitus for chronic glucose lowering, shows promise in decreasing seizure severity and duration. [23] This study, however, shows a differential between side of seizure onset and glucose levels, with one side, the right, consistently lower in glucose at time of seizure than the left. In our patient this implies a more complex relationship than seizure betterment by glucose lowering.
Do ultradian influences help provoke seizure-induction?
Focal seizure susceptibility is influenced by circadian and ultradian cycles mediated during the study, but may at least permit speculation about how sleep staging could drive a sleep vs. wake glucose requirement in differing brain areas.
Perhaps the most relevant data on this shows localized but not lateralized ultradian patterns in a recent study of seizure times in RNS patients. Neocortical temporal and frontal onset patients showed seizure increases between 00:00 and 05:00 AM, and mesial temporal patients more often displayed seizure activity in day/wake time. [26] Our index patient has similar ultradian trends (Figure 2 Is there a network that links ultradian cycles, glucose levels and seizure onset locations?
If there was a linking network between cortex, wake/sleep regulation and glucose control one might presume the hypothalamus must be involved. The arcuate nucleus and lateral hypothalamus helps regulate wake-sleep states and feeding behaviors. [11, [23] [24] [26] [27] [28] [29] [30] Orexin, a key arousal/feeding/wake/sleep influencing neuropeptide is synthesized in the lateral hypothalamus and levels inversely correlate with serum and CSF glucose. [11, 30] In rats, Orexin receptors are present in hippocampal CA-1 neurons and help trigger their firing [29] . Again from rat studies, orexin receptor mRNA
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14 is present diffusely in the brain-with locations varying from infra limbic cortex, thalamus, and cerebral cortex suggesting diffuse pathways into epileptogenic tissues that might mediate ultradian and glucose influences. [30] What implications do these observations have for future work?
Given this data is convenient rather than common, cohorts of type -1 diabetics with both glucose trends may be important, specifically in altering surveillance thresholds or for warning of heightened seizure susceptibility. Finally, elevated glucose and left hippocampal events more often spread contralaterally, implying that stimulation pathways for LFS in this patient should be stronger
Concessions and limitations
There are numerous issues beyond our control in this study. For instance variable insulin dosing, time of anti-seizure drug use, setting changes on the RNS or CGM calibrations, the tendency of the RNS to overwrite long events or seizures, inability to otherwise correlate inflammatory, autoimmune, menstrual, circadian or ultradian variabilities, use of other medications, the inability to accurately measure glucose directly in our patient's CNS tissues (or alternatively delays between CGM tissue glucose vs CNS glucose) fat/protein/glucose/AED absorption issues in the setting of inflammatory bowel disease, and perhaps most importantly over the study duration, changes in her underlying epilepsy. We are assuming those effects randomize over the duration and number of events studied and with two-tailed statistical methods.
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Conclusion
In this convenience sample a type I diabetic with hippocampal RNS electrodes showed variations by side of seizure onset that were both ultradian and related to tissue glucose. The right side, which we presume may be measuring neocortical seizures, shows perhaps the most vulnerability to glucose, with seizure provocation at relatively ower glucose levels and earlier AM times when compared to the control or left-sided data. Seizures (or RNS stimulations) do little to alter tissue glucose post events. Further study of how glucose impacts seizure control will be important to further clarify this finding. Table 1 : Glucose levels at time of seizure as well as immediately after seizure by side of detected seizure. 
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